An internationally recognised cancer researcher and consultant oncologist, Charlie brings experience working at the interface of discovery science and patient care. His appointment reflects the Crick’s long‑standing commitment to strengthening the links between fundamental laboratory research and clinical impact.

Charlie leads the Cancer Evolution and Genome Instability Laboratory at the Crick, where his team is focused on understanding how cancers evolve over time, including how they are first initiated. They are bringing together large‑scale patient data, artificial intelligence tools and model systems to answer some of the biggest challenges in oncology, knowledge that is vital for improving diagnosis, treatment, and even prevention of the disease.

In his new role, Charlie will work closely with the CEO, Edith Heard, and will shape and advance the Crick’s clinical strategy, supporting closer collaboration with university and NHS partners, and expanding the institute’s training for clinician scientists.

“The Crick is a hugely exciting place to be a clinical academic,” says Charlie. “As clinicians, we’re used to seeing things from the top down. But here we can learn the rules of discovery science, taking clinical questions and addressing them from the ground up at the molecular level. There are so many examples of how clinical discovery research has transformed our understanding of human biology. Armed with sophisticated model systems and innovations in the applications of AI, we’re at the start of a revolution in the life sciences, and clinicians have a vital role to play.”

Under Peter’s leadership as Clinical Director, the Crick has built a vibrant clinical research community, establishing its partnerships with hospitals and universities, and helping embed clinicians at all career stages within a discovery research environment. 

“All of this is made possible because of Peter’s legacy. I have thoroughly enjoyed our time working together and I hope to carry forward his enthusiasm for training the next generation of clinical academics," adds Charlie

"I would like to thank Peter for the pivotal role he played in building the Crick’s research culture and ensuring that insights from medicine and human biology are embedded across our research. I am hugely grateful for his leadership and the foundations he put in place.Charlie is exceptionally well placed to continue and build on this work, with a deep commitment to collaboration and strong scientific vision. I am delighted to see him step into this role. His own contributions to cancer research have shaped our understanding of cancer biology, and he is a brilliant role model for clinicians who want to combine rigorous science with real impact for patients.”  Edith Heard, Director and CEO of the Crick